No annual revenue total was found in MiNK Therapeutics, Inc.'s SEC filings.
MiNK Therapeutics, Inc. (INKT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income (TTM)
$-11.36M
-0.8% vs year-ago TTM
Operating cash flow (TTM)
$-6.83M
+10.5% vs year-ago TTM
Free cash flow
$-15.84M
+17.2% vs prior year
EPS (TTM)
$-2.40
+15.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.97M
+25.2% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1840229
- Former names
- AgenTus Therapeutics, Inc. (until Mar 18, 2021); AgenTus Therapeutics, Inc. (until Mar 18, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$12.6M | -$11.3M | -$22.9M | -$30.9M | -$28.4M |
| Net income | -$12.5M | -$10.8M | -$22.5M | -$28.0M | -$30.2M |
| Diluted EPS | -$2.93 | -$2.86 | -$6.54 | -$0.83 | — |
| Operating cash flow | -$5.9M | -$9.6M | -$15.8M | -$18.9M | -$12.8M |
| Free cash flow | — | — | -$15.8M | -$19.1M | -$13.1M |
| Total assets | $14.2M | $5.7M | $4.6M | $21.5M | $40.2M |
| Stockholders' equity | -$14.2M | -$19.6M | -$18.1M | -$401,303 | $23.8M |
| Cash and investments | $13.4M | $4.6M | $3.4M | $19.6M | $38.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 265 MiNK Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.